Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations
- Identify patients with known asbestos exposure at early stages of disease development
(i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural
- Determine the expression levels of tumor-associated proteins in these patients.
- Analyze samples of serum and pleural effusions obtained from these patients.
- Determine the proteomic profile of samples obtained from these patients.
- Determine the molecular mechanisms associated with the regulation of the extracellular
matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix
metalloproteins) involved in disease onset and progression.
OUTLINE: This is a multicenter study.
Patients undergo collection of body cavity fluid, including pleural effusion, and blood.
Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available,
are analyzed for proteomic profile, gene expression profile, and tumor-associated protein
PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
Observational Model: Case Control, Time Perspective: Prospective
Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseases
At time of analysis
Anil Wali, PhD
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|